Origin Therapeutics Holdings Inc. (the “Company” or “Origin”) (CSE: ORIG) is pleased to announce that, in connection with the proposed business combination transaction (the “Transaction”) with Safe Supply Streaming Co Ltd. (“Safe Supply”), all matters submitted to shareholders for approval as set out in detail in the Company’s management information circular dated August 1, 2023 (“Circular”) were approved at the annual general and special meeting of the shareholders of the Company held on August 31, 2023 (the “Meeting”). Further information regarding the resolutions passed at the Meeting can be found in the Circular, which is available on the Company’s profile on SEDAR+ at www.sedarplus.ca.
In connection with the Transaction, Hyperion Capital Inc. provided a fairness opinion to the Board of Directors of the Company, to the effect that, subject to the assumptions, limitations and qualifications set out in such opinion, the consideration to be paid pursuant to the Transaction and the contingent value rights to be received by the shareholders of Origin in connection with the Transaction are fair, from a financial point of view, to the shareholders of Origin.
Subject to certain closing conditions, the Transaction is expected to close in early September 2023.
About Origin Therapeutics
Origin is an investment issuer that has historically focused on making equity investments in psychedelics-industry-related companies to provide investors with diverse exposure to the sector. On December 8, 2022, Origin announced that its board of directors had initiated a review process to consider, review and evaluate strategic alternatives for Origin.